Sunepitron

Sunepitron

Sunepitron
Systematic (IUPAC) name
1-{[2-(pyrimidin-2-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methyl}pyrrolidine-2,5-dione
Clinical data
Legal status
  • Uncontrolled
Routes Oral
Identifiers
CAS number
ATC code None
PubChem
ChemSpider
UNII  YesY
KEGG
ChEMBL
Chemical data
Formula C17H23N5O2 
Mol. mass 329.40 g/mol

Sunepitron (CP-93,393) is a combined 5-HT1A receptor agonist and α2-adrenergic receptor antagonist.[1][2] It was previously under development by Pfizer for the treatment of depression and anxiety.[3] It made it to phase III clinical trials before being discontinued.[2][3]

Synthesis

Sunepitron can be synthesized from a pyridine dicarboxylic acid:[4]

See also

References

  1. ^ Goodnick PJ (July 1999). "Psychopharmacology of depression in the next millennium". CNS Spectrums 4 (7): 21–35.  
  2. ^ a b Stahl, S. M. (2000). Essential psychopharmacology: neuroscientific basis and practical application. Cambridge, UK: Cambridge University Press.  
  3. ^ a b Kaplan, Eliot F.; Turkington, Carol (2001). Making the antidepressant decision: how to choose the right treatment option for you and your loved ones. Chicago, Ill: Contemporary Books.  
  4. ^ G.N. Bright, K.A. Desai, U.S. Patent 5,122,525 (1992)